重组人血管内皮抑制素治疗瘢痕疙瘩的临床观察

发布时间：2018-06-01 12:11

本文选题：瘢痕疙瘩 + 重组人血管内皮抑制素　；参考：《西南医科大学》2017年硕士论文

【摘要】：目的:探讨重组人血管抑制素治疗瘢痕疙瘩的有效性及安全性。方法:将2015年1月-2016年1月在南充市中心医院就诊的瘢痕疙瘩患者64例按随机数字法分为观察组和对照组,各组32例。两组患者均进行超脉冲二氧化碳点阵激光治疗。术前、术后测量计算瘢痕表面积并建电子档记录,多病灶按单个之和计算总面积,签署沟通记录与操作同意书,局部清洁皮肤并外用表面麻醉药物复方利多卡乳膏,麻醉显效后设置治疗参数(能量、密度及脉冲频率)进行治疗,治疗后给予局部冷敷降温及外涂莫匹罗星软膏预防感染,对照组患者常规给予口服抗氧化药物维生素C和抗菌药物治疗;观察组患者在对照组抗氧化药物维生素C和抗菌药物治疗基础上,加用重组人血管内皮抑制素注射液瘢痕内注射,注射剂量为0.1~0.2 mg/cm2,每月治疗1次,完成3次治疗。比较两组患者的临床疗效,症状改善评分比较,创面愈合时间比较;治疗满意度比较,以及不良反应发生情况。结果:观察组和对照组患者的总有效率(93.75%vs.87.50%)和不良反应发生率(12.50%vs.9.38%)比较,差异均无统计学意义(P0.05)。对比治疗后3月,观察组临床症状包括瘙痒和灼痛感改善评分均高于对照组,差异均有统计学意义(P0.05),观察组患者的创面结痂时间、脱痂时间及创面完全愈合时间比较均明显短于对照组,差异均有统计学意义(P0.05),观察组的满意度优于对照组。结论:重组人血管内皮抑制素结合激光治疗瘢痕疙瘩的临床疗效与单纯激光治疗无显著差异,但能够缩短创面愈合时间,缓解瘢痕疙瘩的瘙痒及疼痛,且用安全性较好。
[Abstract]:Objective: to investigate the efficacy and safety of recombinant human angiostatin in the treatment of keloid. Methods: from January 2015 to January 2016, 64 keloid patients in Nanchong Central Hospital were randomly divided into observation group (n = 32) and control group (n = 32). Two groups of patients were treated with super pulse carbon dioxide lattice laser. Before and after operation, the surface area of scar was measured and an electronic record was established. The total area of multiple lesions was calculated according to a single sum, and the communication record and operation consent were signed, the skin was locally cleaned and the topical anesthetic compound lidoca cream was used. The parameters (energy, density and pulse frequency) were set up after the anesthesia became effective. After the treatment, local cold compress and mupiroxine ointment were given to prevent infection. The patients in the control group were routinely treated with oral antioxidation drug vitamin C and antimicrobial agents, while the patients in the observation group were treated with vitamin C and antimicrobial drugs on the basis of the antioxidant drugs in the control group. Recombinant human vascular endotheliostatin injection was injected into the scar with a dose of 0.1 渭 m ~ (2) mg / cm ~ (-2) once a month for 3 times. The clinical efficacy, symptom improvement score, wound healing time, treatment satisfaction and adverse reactions were compared between the two groups. Results: there was no significant difference in the total effective rate (93.75vs.87.50) and the incidence of adverse reactions (12.50 vs 9.38) between the observation group and the control group (P 0.05). The scores of clinical symptoms including pruritus and burning pain in the observation group were higher than those in the control group three months after the contrast treatment, and the difference was statistically significant (P 0.05). The scabbing time of the patients in the observation group was higher than that in the control group. The time of eschar removal and the time of complete wound healing were significantly shorter than those of the control group (P 0.05). The satisfaction of the observation group was better than that of the control group. Conclusion: the clinical efficacy of recombinant human vascular endothelial inhibin combined with laser in treating keloid is not significantly different from that of laser alone, but it can shorten the wound healing time, relieve the pruritus and pain of keloid, and have good safety.
【学位授予单位】：西南医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R622

【参考文献】